Skip to content
Triangle logo TriangleGet started
← Study library

NCT03481556 · REGISTRY CONDITION SEARCH

Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE1, PHASE2
Status at capture
TERMINATED
Registry last update
2022-12-19

This is an open-label Phase 1/2a study which will enroll patients that have relapsed or relapsed-refractory multiple myeloma to combination regimens of melflufen with currently approved agents. Patients will receive either melflufen+dexamethasone+bortezomib or melflufen+dexamethasone+daratumumab.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Phase 1: Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)

→

outcome · POSTED

Phase 2: Overall Response Rate (ORR)

→

outcome · POSTED

Best Response (BR)

→

outcome · POSTED

Duration of Response (DOR)

→

outcome · POSTED

Time to Response (TTR)

→

outcome · POSTED

Progression-Free Survival (PFS)

→

outcome · POSTED

Overall Survival (OS)

→

outcome · POSTED

Duration of Clinical Benefit (DOCB)

→

outcome · POSTED

Time to Progression (TTP)

→

outcome · POSTED

Clinical Benefit Rate (≥ Minimal Response)

→

outcome · POSTED

Time to Next Treatment (TTNT)

→

outcome · POSTED

Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: 1. Male or female, age 18 years or older 2. A prior diagnosis of multiple myeloma with documented disease progression in need of treatment at time of screening 3. One to four prior lines of therapy 4. Measurable disease defined as any of the following: * Serum monoclonal protein ≥ 0.5 g/dL by serum protein electrophoresis (SPEP) * ≥ 200 mg/24 hours of monoclonal protein in the urine on 24-hour urine electrophoresis (UPEP) * Serum free light chain (SFLC) ≥ 10 mg/dL AND abnormal serum kappa to lambda free light chain ratio 5. Life expectancy of ≥ 6 months 6. ECOG performance status ≤ 2. (Patients with lower performance status based solely on bone pain secondary to multiple myeloma may be eligible following consultation and approval of the medical monitor) 7. Patient is a female of childbearing potential (FCBP)\* with a negative serum or urine pregnancy test prior to initiation of therapy and agrees to practice appropriate methods of birth control, or the patient is male and agrees to practice appropriate methods of birth control 8. Ability to understand the purpose and risks of the study and provide signed and dated informed consent 9. 12-lead Electrocardiogram (ECG) with QT interval calculated by Fridericia Formula (QTcF) interval of ≤ 470 msec 10. Adequate organ function with the following laboratory results during screening (within 21 days) and immediately before study drug administration on Cycle 1 Day 1: * Absolute neutrophil count (ANC) ≥ 1,000 cells/mm3 (1.0 x 109/L) (Growth factors cannot be used within 10 days (14 days for pegfilgrastim) prior to initiation of therapy) * Platelet count ≥ 75,000 cells/mm3 (75 x 109/L) (without required transfusions during the 10 days prior to initiation of therapy) * Hemoglobin ≥ 8.0 g/dl (red blood cell (RBC) transfusions are permitted) * Total Bilirubin ≤ 1.5 x upper limit of normal (ULN), or patients diagnosed with Gilbert's syndrome, that have been reviewed and approved by the medical monitor * AST/SGOT and ALT/SGPT ≤ 3.0 x ULN * Renal function: Estimated creatinine clearance by Cockcroft-Gault formula ≥ 45 mL/min and serum creatinine ≤ 2 mg/dL 11. Must have, or be willing to have an acceptable central catheter. (Port a cath, peripherally inserted central catheter \[PICC\] line, or central venous catheter) Regimen A 12. Must be intolerant or refractory to a prior IMiD; refractory defined as failure to respond (MR or better) or progression while on therapy or within 60 days of last dose. Regimen B 13. Must have had a prior IMiD and a proteasome inhibitor (PI); alone or in combination and must be refractory or intolerant to an IMiD, PI or both. * (FCBP) is any sexually mature female who: 1) has not undergone a hysterectomy or bilateral oophorectomy or 2) has not been naturally postmenopausal (not having menstrual cycles due to cancer therapy does not rule out childbearing potential) for at least 24 consecutive months. Exclusion Criteria: 1. Primary refractory disease (i.e. never responded with ≥ MR to any prior therapy) 2. Evidence of mucosal or internal bleeding and/or are platelet transfusion refractory (i.e. platelet count fails to increase by \> 10,000 cells/mm3 after transfusion of an appropriate dose of platelets) 3. Any medical conditions that, in the Investigator's opinion, would impose excessive risk to the patient or would adversely affect his/her participating in this study. Examples of such conditions are: a significant history of cardiovascular disease (e.g., myocardial infarction, significant conduction system abnormalities, uncontrolled hypertension, ≥ Grade 3 thromboembolic event in the last 6 months) 4. Known active infection requiring parenteral or oral anti-infective treatment within 14 days of initiation of therapy 5. Other malignancy diagnosed or requiring treatment within the past 3 years with the exception of adequately treated basal cell carcinoma, squamous cell skin cancer, carcinoma in-situ of the cervix or breast or very low and low risk prostate cancer in active surveillance 6. Pregnant or breast-feeding females 7. Serious psychiatric illness, active alcoholism, or drug addiction that may hinder or confuse compliance or follow-up evaluation 8. Known human immunodeficiency virus or active hepatitis B or C viral infection 9. Concurrent symptomatic amyloidosis or plasma cell leukemia 10. POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes) 11. Previous cytotoxic therapies, including cytotoxic investigational agents, for multiple myeloma within 3 weeks (6 weeks for nitrosoureas) prior to initiation of therapy. The use of live vaccines within 30 days before initiation of therapy. IMiDs, PIs and or corticosteroids within 2 weeks prior to initiation of therapy. Other investigational therapies and monoclonal antibodies (mAb) within 4 weeks of initiation of therapy Prednisone up to but no more than 10 mg orally once daily (q.d.) or its equivalent for symptom management of comorbid conditions is permitted but dose should be stable for at least 7 days prior to initiation of therapy 12. Residual side effects to previous therapy \> Grade 1 prior to initiation of therapy (Alopecia any grade and/or neuropathy Grade 1 without pain are permitted) 13. Prior peripheral stem cell transplant within 12 weeks of initiation of therapy 14. Prior allogeneic stem cell transplantation with active graft-versus-host- disease 15. Prior major surgical procedure or radiation therapy within 4 weeks of initiation of therapy (this does not include limited course of radiation used for management of bone pain within 7 days of initiation of therapy) 16. Known intolerance to the required dose and schedule of steroid therapy as determined by the investigator 17. Prior treatment with melflufen Regimen A 18. Refractory to a PI in the last line of therapy prior to enrollment in this trial; refractory defined as failure to respond (MR or better) or progression while on therapy or within 60 days of last dose 19. History of allergic reaction/hypersensitivity attributed to compounds containing boron, mannitol, polysorbate 80 or sodium citrate dihydrate Regimen B 20. Prior exposure to an antiCD-38 mAb 21. Chronic obstructive pulmonary disease (COPD) with a Forced Expiratory Volume in 1 second (FEV1) less than 50% of predicted normal 22. Moderate or severe persistent asthma within the past 2 years, or currently has uncontrolled asthma of any classification 23. ≥ Grade 3 conduction system abnormalities unless patient has a pacemaker 24. Active hepatitis B (defined as HBsAg+) or those at risk for reactivation (HBsAg-, Anti- HBs+, Anti-HBc+) * Patients with prior hepatitis B vaccine are permitted (defined as HBsAg-, Anti-HBs+, Anti-HBc-) * Non-active hepatitis B (HBsAg-, Anti-HBs+, Anti-HBc+) may only be enrolled after approval of the sponsor and consideration of risk of reactivation (additional screening and monitoring for reactivation of Hepatitis B and consultation with a liver disease specialist may be required)
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Melflufen 30 mg and 40 mg or 20 mg i.v. Day 1 of each 28-day cycle in combination with bortezomib at 1.3mg/m² S.Q. on Days 1, 4, 8, 11 and dexamethasone 20 mg (12 mg ≥ 75 years) Days 1, 4, 8, 11 and 40 mg (20 mg ≥ 75 years) on Day 15 and 22 of each 28-day cycle.
    intervention Names
    1. Drug: Melphalan flufenamide (Melflufen)
    2. Drug: Dexamethasone
    3. Drug: Bortezomib
    label
    A (melflufen+bortezomib+dex)
    type
    EXPERIMENTAL
  2. description
    Melflufen 30 mg and 40 mg or 20 mg i.v. Day 1 of each 28-day cycle in combination with daratumumab 16 mg/kg weekly for 8 doses, every other week for 8 doses and then once every 4 weeks. Dexamethasone p.o. 40 mg weekly (20 mg weekly for patients age ≥ 75 years).
    intervention Names
    1. Drug: Melphalan flufenamide (Melflufen)
    2. Drug: Dexamethasone
    3. Drug: Daratumumab
    label
    B (melflufen+daratumumab+dex)
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. A (melflufen+bortezomib+dex)
    2. B (melflufen+daratumumab+dex)
    description
    Intravenous infusion
    name
    Melphalan flufenamide (Melflufen)
    type
    DRUG
  2. arm Group Labels
    1. A (melflufen+bortezomib+dex)
    2. B (melflufen+daratumumab+dex)
    description
    Oral tablets
    name
    Dexamethasone
    other Names
    1. Dex
    2. Fortecortin
    3. Decadron
    type
    DRUG
  3. arm Group Labels
    1. A (melflufen+bortezomib+dex)
    description
    Subcutaneous administration
    name
    Bortezomib
    other Names
    1. Velcade
    type
    DRUG
  4. arm Group Labels
    1. B (melflufen+daratumumab+dex)
    description
    Intravenous infusion
    name
    Daratumumab
    other Names
    1. Dara
    2. Darzalex
    type
    DRUG
Study design
allocation
NON_RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
56
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Toxicity was graded according to the National Cancer Institute - Common Terminology Criteria for Adverse Events Version 4.03. DLT criteria that apply to Regimens A and B: * Grade 3 non-hematologic toxicity preventing the administration of \> 1 dose of bortezomib or daratumumab during the 1st cycle. * Grade 4 or greater non-hematologic toxicity. * Grade 4 thrombocytopenia (platelet count \< 25,000 cells/ mm\^3) preventing the administration of \> 1 dose of bortezomib or daratumumab during the 1st cycle or with clinically significant bleeding during the 1st cycle. * Grade 4 neutropenia (ANC \< 500 cells/mm\^3), lasting more than 7 days during the 1st cycle. * Greater than 14 days' delay to meet the criteria for the start of a new cycle (Cycle 2) due to toxicity.
    measure
    Phase 1: Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)
    time Frame
    Cycle 1: Day 1 to Day 28
  2. description
    ORR was defined as the percentage of participants who achieved a best confirmed response of Partial Response (PR) or better.
    measure
    Phase 2: Overall Response Rate (ORR)
    time Frame
    Until disease progression, death or initiation of subsequent therapy (a maximum of 194.3 weeks)
secondary Outcomes
  1. description
    BR defined by International Myeloma Working Group Uniform Response Criteria. BR= Complete Response (CR)/Stringent CR (sCR) defined as below negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in bone marrow/plus normal free light chain (FLC) ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence, Very Good Partial Response (VGPR)= serum and urine M-protein detectable by immunofixation but not on electrophoresis or \> 90% reduction in serum M-protein plus urine M-protein level \< 100 mg/24 hours, Partial Response (PR)= a \> 50% reduction of serum M-protein and reduction in 24 hours urinary M-protein by \> 90% or to \< 200 mg/24 hours, Minimal Response (MR), Stable Disease (SD)= not meeting the criteria for other response options, Progressive Disease (PD)= increase of \> 25% from lowest response value in serum/urine M-component or bone marrow plasma cell percentage, or non-evaluable.
    measure
    Best Response (BR)
    time Frame
    Until disease progression, death or initiation of subsequent therapy (a maximum of 194.3 weeks)
  2. description
    DOR is defined for participants with confirmed objective response (PR or better, which includes PR, VGPR, CR and sCR) as the time from the first documentation of objective response to the first documentation of objective progression or to death due to any cause, whichever occurs first.
    measure
    Duration of Response (DOR)
    time Frame
    Until disease progression, death or initiation of subsequent therapy (a maximum of 194.3 weeks)
  3. description
    Time from Cycle 1 Day 1 to a response of PR or better.
    measure
    Time to Response (TTR)
    time Frame
    Until disease progression, death or initiation of subsequent therapy (a maximum of 194.3 weeks)
  4. description
    PFS was defined as the time in months from date of initiation of therapy to the earlier of confirmed disease progression or death due to any cause.
    measure
    Progression-Free Survival (PFS)
    time Frame
    Until disease progression, death or initiation of subsequent therapy (a maximum of 194.3 weeks)
  5. description
    Time from the first dose of melflufen to death due to any cause.
    measure
    Overall Survival (OS)
    time Frame
    Up to 24 months following confirmed disease progression, or initiation of subsequent therapy (a maximum of 198.9 weeks)
  6. description
    DOCB was defined as time in months from the first evidence of confirmed assessment of sCR, CR, VGPR, PR or MR to first confirmed disease progression, or to death due to any cause.
    measure
    Duration of Clinical Benefit (DOCB)
    time Frame
    Until disease progression, death or initiation of subsequent therapy (a maximum of 194.3 weeks)
  7. description
    TTP defined as time from first dose to first documented confirmed progression.
    measure
    Time to Progression (TTP)
    time Frame
    Until disease progression, death or initiation of subsequent therapy (a maximum of 194.3 weeks)
  8. description
    ≥ Minimal response for participants included sCR, CR, VGPR, PR and MR.
    measure
    Clinical Benefit Rate (≥ Minimal Response)
    time Frame
    Until disease progression, death or initiation of subsequent therapy (a maximum of 194.3 weeks)
  9. description
    Defined as time from date of initiation of therapy to start of next line of therapy.
    measure
    Time to Next Treatment (TTNT)
    time Frame
    Until death or initiation of subsequent therapy (a maximum of 194.3 weeks)
  10. description
    TEAEs were defined as adverse events (AEs) that started after the first dose of study medication was administered and within 30 days of the last administration of the study treatment or before start of subsequent anticancer treatment (whichever occurred first) or that worsened after the first dose of study medication was administered.
    measure
    Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)
    time Frame
    Cycle 1 Day 1 up to a maximum of 198.9 weeks
Full study description
brief Summary
This is an open-label Phase 1/2a study which will enroll patients that have relapsed or relapsed-refractory multiple myeloma to combination regimens of melflufen with currently approved agents. Patients will receive either melflufen+dexamethasone+bortezomib or melflufen+dexamethasone+daratumumab.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-c369873b98084be062ea
      requested nct id
      NCT03481556
      primary nct id
      NCT03481556
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      payload sha256
      e7f74fa8cf421c224d4a50f8f36efdf6e5dbb1b37516c5281be0f6ca4de18f95
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-c369873b98084be062ea
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT03481556
      occurrences
      1. context exact
        NCT03481556
        end
        11
        exact text
        NCT03481556
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      source json pointer
      /studies/954/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      e09bdfd90fe4ccfddbaa7bb4203c611df8e93f3ceb9e39ac2aecc1f068aebf17

    Preserved source evidence · Not medical advice